Zhaozhong Zhu

Assistant Professor @MassGenBrigham, asthma, genetics, microbiome, multi-omics, dad, husband, swimmer

[James D Chalmers @ProfJDChalmers]

First day and already I know this will be my favourite session of the congress
Thank you to all of our patients and tk @EuropeanLung - you’ve changed the clinical and scientific landscape in bronchiectasis and many other respiratory diseases ❤️

[ERS @EuroRespSoc]

What a fantastic third day we’ve had here at #ERSCongress2026!

Thank you to everyone who joined us for another brilliant day. We look forward to seeing you tomorrow!

#ERSCongress #Barcelona

[ERS publications @ERSpublications]

Azithromycin treatment enhanced epithelial IFN–β/λ responses and reduced IL–33 concentration after rhinovirus infection in asthma – dual effects supporting its role in boosting antiviral immunity and reducing type 2 inflammation to prevent exacerbations https://t.co/ZXGvPXZTb0

[Don Sin @donsin4]

Podcast August 2026: Fentanyl or morphine or placebo for persistent dyspnoea in #COPD. "There is an effect of morphine or opioids on breathlessness, but it does not translate in a relevant and significant effect in daily life treatment..." https://t.co/v4g92ym3IL

[Christina Thornton @CThornton32]

Very excited for this study to be out. In this study, we looked to evaluate the epidemiology of bronchiectasis in Alberta; representing the first population based study of adults in bronchiectasis in Canada. 🇨🇦 🫁 @UCalgaryMed @SnyderInstitute

https://t.co/GYcc6ZWCf5

[James D Chalmers @ProfJDChalmers]

Further evidence of the challenges in targeting the mighty neutrophil.
Our trial of Myeloperoxidase (MPO) inhibition in COPD found no efficacy, and increased pneumonia
Just published in @ERSpublications
https://t.co/NMFM4UAxCm

[James D Chalmers @ProfJDChalmers]

The Chalmers laboratory at the University of Oxford is looking for an outstanding postdoctoral research to lead an ambitious research project to find new therapies targeting mucus/MUC5AC in bronchiectasis
We are a supportive and friendly team
Apply now!
https://t.co/PEJfoqOAkz

[ERS @EuroRespSoc]

⏳ Only one week left to vote for the next ERS Vice President!

🗳️ Members have until Sunday, 2 August 2026 (23:59 CEST) to cast their vote via the 'Elections' tab on myERS: https://t.co/Bo5R5hRYqD

[Zhaozhong Zhu @hellofuture100]

@CThornton32 @UCalgaryMed Congratulations, Dr. Thornton! 🎉

[James D Chalmers @ProfJDChalmers]

join us for World bronchiectasis day!

[James D Chalmers @ProfJDChalmers]

A primary care summary of the European Respiratory Society guidelines for bronchiectasis 2025
A collaboration with GP colleagues to improve the quality of care for people with bronchiectasis in primary care
@FionaMosgrove @MereteLong @AlibertiStefano
https://t.co/yaZhUCnrl2

[Don Sin @donsin4]

Large scale proteomics reveal new biomarkers and therapeutic targets in #COPD. What are these biomarkers? Many in the metabolic pathway. Why? Here Xuekui and I go into the reasons behind this observation https://t.co/e9YYsRqADy

[James D Chalmers @ProfJDChalmers]

The European Respiratory Journal impact factor, released today, has increased to 23.8, its highest ever level outside of the COVID-19 pandemic.

We are incredibly proud of the high scientific impact of the ERJ @ERSpublications and very grateful to authors, reviewers, our outstanding publication office team and our outstanding editors.

Respiratory Journal IFs
Lancet Resp 34.7
ERJ 23.8
Journal of thoracic Oncology 23.3
AJRCCM 21.7
ERR 10.8
CHEST 9.8
Thorax 9.1

@EuroRespSoc @donsin4

[James D Chalmers @ProfJDChalmers]

Join my new group at the University of Oxford! We are looking for a data analyst to examine our world leading EMBARC database. Work with experts to find new insights in lung disease with big data!
Join us!
https://t.co/4MFt6oHXQV
@MereteLong @beccahull_

[James D Chalmers @ProfJDChalmers]

Get involved in the exciting world of respiratory research
The Chalmers laboratory at University of Oxford is looking for a senior research technician
Work on world leading translational research in a supportive team
Join us!
https://t.co/NhdODLXXKT

[Don Sin @donsin4]

What is the relevance of mucus plugs in #asthma and #COPD. Hear the answers from Dr Fahy in the latest podcast

[Don Sin @donsin4]

Astegolimab and the new era of biologics in COPD care - The Lancet.

Here, Clarus and I discuss the relevance of these trials in #COPD and what’s needed to effectuate precision therapy in COPD. https://t.co/I40UedsBA5

[ERS @EuroRespSoc]

📺 Benefit from a 30-minute update of all the most significant developments in respiratory medicine with Respiratory News Live!

The next broadcast will take place on 19 May (18:30 CEST) – don’t miss it, register for FREE: https://t.co/TYSwiBu79q

[Don Sin @donsin4]

LAM is a genetic disease caused by mutations in the TSC2 gene

[Zhaozhong Zhu @hellofuture100]

@ProfJDChalmers Congratulations on your great tenure, James! Thanks for your amazing leadership at ERJ!